SH2D5 Antibody

What is SH2D5 and why is it significant in cancer research?

SH2D5 (Src Homology 2 Domain Containing Protein 5) is a mammalian-specific scaffolding protein that contains an N-terminal phosphotyrosine-binding domain and a C-terminal Src homology 2 (SH2) domain. Despite harboring two potential phosphotyrosine recognition domains, SH2D5 binds minimally to phosphotyrosine ligands, likely due to the absence of a conserved phosphotyrosine-binding arginine residue in the SH2 domain .

SH2D5 has emerged as a significant research target because:

• It is aberrantly expressed in multiple cancer types, particularly lung adenocarcinoma (LUAD) and hepatocellular carcinoma (HCC)

• High SH2D5 expression correlates with poor prognosis in LUAD and HCC patients

• It plays critical roles in cancer cell proliferation, migration, and invasion

• It interacts with immune infiltration processes and may affect tumor microenvironment

• It functions in key signaling pathways, including AKT in LUAD and STAT3 in HCC

Recent studies have established clear differential expression patterns:

In LUAD:

• SH2D5 shows prominent up-regulation in LUAD tissues compared to normal lung tissues

• This pattern has been validated through multiple methodologies (qRT-PCR, IHC, Western blot)

• Expression analysis via TCGA and GEO databases consistently shows elevation of SH2D5 in LUAD tissues versus normal tissues

In HCC:

• Higher levels of SH2D5 are found in HBV-associated HCC liver tissues than in adjacent non-tumor tissues

• Expression increases progressively from normal liver cells to low-metastatic HCC cells, and finally to highly-metastatic HCC cells

When designing experiments with SH2D5 antibodies, include appropriate normal tissue controls and consider tissue-specific expression patterns to properly interpret results.

How should I optimize SH2D5 antibody protocols for immunohistochemistry of cancer tissues?

Optimizing IHC protocols for SH2D5 requires careful consideration of several parameters:

Recommended IHC Protocol:

• Sample preparation: Use formalin-fixed paraffin-embedded (FFPE) sections, deparaffinized and rehydrated

• Antigen retrieval: Employ microwave treatment for antibody-binding epitope retrieval

• Blocking: Pretreat sections with 3% H₂O₂ for 20 min, then preincubate with 10% goat serum to block nonspecific binding

• Primary antibody: Use rabbit anti-SH2D5 (e.g., ab170881, Abcam) at 1:100 dilution

• Secondary detection: Apply biotinylated anti-rabbit secondary antibody followed by streptavidin-horseradish peroxidase

• Visualization: Use DAB as chromogen and hematoxylin for counterstaining

Scoring methodology:
Score staining based on both intensity and extent of SH2D5 expression:

• Intensity: 0 (negative), 1 (weak), or 2 (strong)

• Extent: 0 (negative), 1 (1-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%)

• Final score: 0-1 (−), 2-3 (±), 4-5 (+), or 6-7 (++)

This scoring system allows for clinically relevant stratification of SH2D5 expression that correlates with patient outcomes.

What are the optimal approaches for investigating SH2D5's role in immune infiltration?

To investigate SH2D5's relationship with immune infiltration, several methodological approaches are recommended:

• Computational analysis:

  • Apply CIBERSORT algorithm to detect the composition of invasive immune cells in specimens

  • Use single-sample Gene Set Enrichment Analysis (ssGSEA) to assess the infiltration status of 22 immune cell types

  • Employ Tumor Immune Estimation Resource (TIMER) for correlation analysis between SH2D5 expression and immune infiltration

• Statistical methods:

  • Apply Spearman correlation analysis to determine associations between SH2D5 expression and:

    • Immune cell infiltration (dendritic cells, plasma cells, mast cells, T cells, etc.)

    • Immune checkpoint genes (CD40LG, TNFSF15, CD276, CD70)

• Validation experiments:

  • Confirm computational findings through immunohistochemical staining for immune cell markers

  • Perform flow cytometry on tumor samples with varying SH2D5 expression levels to quantify immune cell populations

  • Use siRNA-mediated SH2D5 knockdown to observe effects on immune cell recruitment in vitro and in vivo

Results from these approaches can reveal critical insights, such as the negative correlation between SH2D5 expression and dendritic cells resting (p<0.001), plasma cells (p<0.001), mast cells resting (p=0.031) and T cells CD4 memory resting (p=0.036) observed in LUAD patients .

How can I design experiments to investigate SH2D5-protein interactions in signaling pathways?

To investigate SH2D5's protein interactions and signaling effects, consider this methodological workflow:

• Co-immunoprecipitation coupled to mass spectrometry (IP-MS):

  • Immunoprecipitate SH2D5 using specific antibodies from cell lysates

  • Identify interacting proteins through mass spectrometry analysis

  • Validate key interactions through reverse co-IP

• Domain-specific interaction mapping:

  • Generate constructs expressing specific domains of SH2D5 (N-terminal PTB domain vs. C-terminal SH2 domain)

  • Perform co-IP experiments to identify domain-specific interactions

  • Use site-directed mutagenesis to validate binding motifs (e.g., NxxF motifs in interaction partners)

• Signaling pathway analysis:

  • For AKT pathway (LUAD): Assess phosphorylation levels of AKT following SH2D5 modulation

  • For STAT3 pathway (HCC): Examine STAT3 phosphorylation at Tyr-705 and downstream signaling following SH2D5 expression changes

  • Employ rescue experiments with pathway activators/inhibitors to confirm SH2D5's role

• Functional validation:

  • Use siRNA-mediated depletion of SH2D5 to observe phenotypic effects

  • Monitor downstream pathway activation through phospho-specific antibodies

  • Assess cellular phenotypes (proliferation, migration, morphology changes)

This multi-layered approach has successfully identified important SH2D5 interactions, such as with the breakpoint cluster region protein (BCR) in neurons and transketolase (TKT) in HCC .

How should I interpret contradictory results between SH2D5 expression and clinical parameters?

When interpreting potentially contradictory results regarding SH2D5 expression and clinical parameters, consider these methodological approaches:

• Multi-cohort validation:

  • Analyze SH2D5 expression across multiple independent patient cohorts

  • Compare findings from different databases (TCGA, GEO, CCLE)

  • Validate with multiple analytical tools (GEPIA, UALCAN, Kaplan-Meier Plotter)

• Stratification by clinical variables:

  • Stratify patients by clinical parameters (tumor stage, gender, smoking status, etc.)

  • Analyze SH2D5's prognostic value within each stratified group

  • Consider confounding variables that may influence outcome metrics

• Multivariate analysis:

  • Employ Cox regression multivariate analysis to identify independent prognostic factors

  • Include key clinical variables (stage, LNM status, age, etc.)

  • Calculate hazard ratios with 95% confidence intervals

Example contradictory finding resolution:
In LUAD, while SH2D5 expression correlated with gender, lymph node metastasis, smoking status, and stage in univariate analyses, multivariate Cox regression confirmed SH2D5 as an independent prognostic factor (HR: 2.16, 95% CI: 1.46-3.18, p=1.03E-04) , suggesting its prognostic value transcends these variables.

What statistical methods are appropriate for analyzing SH2D5 expression in relation to immune infiltration?

For robust statistical analysis of SH2D5 expression and immune infiltration data:

• Correlation analyses:

  • Apply Spearman's correlation analysis to assess relationships between SH2D5 expression and infiltration levels of specific immune cell types

  • Calculate correlation coefficients and p-values for each immune cell population

  • Visualize correlations through scatter plots showing expression vs. infiltration levels

• Comparative analyses:

  • Use t-tests to compare immune cell composition between SH2D5-high and SH2D5-low expression groups

  • Apply ANOVA for multi-group comparisons when stratifying by additional variables

  • Present results as box plots showing immune cell distributions across groups

• Survival analyses:

  • Perform Kaplan-Meier survival analysis stratified by both SH2D5 expression and immune cell enrichment

  • Calculate log-rank tests to determine statistical significance between curves

  • Generate stratified survival curves for combinations of SH2D5 expression and specific immune cell populations

• Integrated analyses:

  • Use ssGSEA scores to quantify immune infiltration

  • Apply CIBERSORT algorithm to estimate relative percentages of immune cells

  • Integrate these findings with clinical outcome data through multivariate models

These approaches revealed that SH2D5 abundance in LUAD correlates with poor prognosis specifically in tumors enriched with B cells, CD4+ T cells, macrophages, and Treg cells, suggesting complex interactions between SH2D5 and the tumor immune microenvironment .

How do I validate SH2D5 antibody specificity and optimize experimental conditions?

Thorough validation of SH2D5 antibody specificity requires a multi-faceted approach:

• Genetic validation approaches:

  • Perform siRNA knockdown experiments to reduce endogenous SH2D5 (as demonstrated in H1299 cells)

  • Create overexpression systems (as shown in A549 and HCC827 cells)

  • Confirm antibody signal changes proportionally with genetic manipulation

• Western blot optimization:

  • Use multiple antibodies targeting different epitopes of SH2D5

  • Include positive controls (transfected cells overexpressing SH2D5)

  • Test antibody in multiple cell lines with varying SH2D5 expression levels

  • Verify signal at the expected molecular weight

• IHC validation protocol:

  • Include appropriate IgG negative controls

  • Test antibody in tissues known to express or lack SH2D5

  • Perform parallel staining with multiple SH2D5 antibodies

  • Compare protein expression with mRNA levels (qRT-PCR)

• Titration testing:

  • For Western blot: Test antibody dilutions (e.g., 1:500, 1:1000, 1:2000)

  • For IHC: Test dilution series (e.g., 1:50, 1:100, 1:200)

  • Document optimal conditions that maximize signal-to-noise ratio

In published studies, researchers validated anti-SH2D5 antibody specificity by comparing signals in normal vs. cancer tissues, and confirming expression changes following genetic manipulation of SH2D5 levels, providing confidence in antibody specificity .

How can I investigate SH2D5's role in epithelial-mesenchymal transition (EMT) in cancer?

To investigate SH2D5's role in EMT, implement this methodological workflow:

• Gene expression analysis:

  • Perform Gene Set Enrichment Analysis (GSEA) to identify associations between SH2D5 and EMT-related gene signatures

  • Use RNA-seq data from cancer tissues with varying SH2D5 expression levels

  • Focus on established EMT marker genes and pathways

• Experimental manipulation of SH2D5:

  • Create SH2D5 overexpression and knockdown models in cancer cell lines

  • Assess changes in EMT markers at protein level:

    • Epithelial markers (E-cadherin, claudins, ZO-1)

    • Mesenchymal markers (N-cadherin, vimentin, fibronectin)

    • EMT transcription factors (Snail, Slug, ZEB1/2, Twist)

  • Analyze cell morphology changes indicative of EMT

• Signaling pathway investigation:

  • Examine AKT pathway activation status following SH2D5 modulation

  • Perform rescue experiments with AKT pathway activators/inhibitors

  • Determine if pathway modulation reverses SH2D5-induced EMT phenotypes

• Functional assays:

  • Migration assays (wound healing, transwell)

  • Invasion assays (Matrigel-coated transwell)

  • Cell scattering assays

  • 3D spheroid formation and invasion assays

Recent studies have demonstrated that SH2D5 promotes the migration and EMT process of LUAD cells through the AKT signaling pathway, suggesting SH2D5 may serve as a crucial potential target for treating metastatic LUAD .

What approaches should I use to study SH2D5's interaction with immune checkpoint pathways?

To investigate SH2D5's relationship with immune checkpoint pathways:

• Correlation analysis:

  • Perform Spearman correlation analysis between SH2D5 expression and immune checkpoint genes

  • Focus on established checkpoint molecules (PD-1, PD-L1, CTLA-4, etc.)

  • Include emerging checkpoint targets (CD40LG, TNFSF15, CD276, CD70)

  • Visualize correlations through heatmaps and correlation plots

• Experimental manipulation:

  • Create SH2D5 knockdown and overexpression models in cancer cells

  • Assess changes in checkpoint molecule expression

  • Co-culture with immune cells to evaluate functional consequences

  • Measure T cell activation markers and cytokine production

• Patient sample analysis:

  • Perform multiplex immunohistochemistry to simultaneously detect SH2D5 and checkpoint molecules

  • Analyze spatial relationships between SH2D5-expressing cells and checkpoint-positive immune cells

  • Correlate expression patterns with patient outcomes and treatment response

• Mechanistic studies:

  • Investigate transcriptional regulation of immune checkpoints following SH2D5 modulation

  • Examine signaling pathway crosstalk (AKT, STAT3) that might link SH2D5 to checkpoint expression

  • Perform chromatin immunoprecipitation to identify potential direct regulation

Research has shown that among immune checkpoints, CD40LG and TNFSF15 present negative correlations with immune infiltrates, while CD276 and CD70 show positive correlations in the context of SH2D5 expression , suggesting complex relationships that warrant further investigation.

How can I design experiments to study SH2D5's prognostic significance across different cancer types?

To comprehensively evaluate SH2D5's prognostic significance across cancer types:

• Multi-cancer bioinformatic analysis:

  • Analyze SH2D5 expression across cancer types using databases:

    • TCGA pan-cancer data

    • GEO datasets

    • CCLE cell line data

  • Compare expression levels between tumor and matched normal tissues

  • Correlate expression with survival metrics (OS, DSS, PFS) across cancer types

• Tissue microarray (TMA) validation:

  • Develop TMAs containing multiple cancer types and corresponding normal tissues

  • Perform standardized IHC with optimized SH2D5 antibody protocols

  • Apply consistent scoring methodology across cancer types:

    • Intensity: 0 (negative), 1 (weak), 2 (strong)

    • Extent: 0-4 scale based on percentage of positive cells

    • Calculate composite scores

• Clinical correlation studies:

  • Collect comprehensive clinical data for each cancer cohort

  • Perform univariate and multivariate Cox regression analyses

  • Calculate hazard ratios with confidence intervals

  • Stratify by cancer stage, grade, and other relevant clinical parameters

• Mechanistic comparison:

  • Investigate if SH2D5's molecular interactions differ between cancer types

  • Compare binding partners (BCR, TKT) across cancer contexts

  • Assess pathway involvement (AKT, STAT3) in different tumor types

Published studies have already established SH2D5's prognostic significance in both LUAD (HR: 2.16, 95% CI: 1.46-3.18, p=1.03E-04) and HBV-HCC, suggesting its potential broader relevance as a pan-cancer prognostic marker.

What are the most common technical issues with SH2D5 antibodies and how can I resolve them?

When working with SH2D5 antibodies, researchers may encounter several technical challenges:

For antibody-specific optimization, follow these steps:

• Titrate antibody concentration for each application

• Test multiple blocking agents (BSA, serum, commercial blockers)

• Optimize incubation times and temperatures

• Include appropriate positive and negative controls

These approaches were successfully implemented in published studies using SH2D5 antibodies across Western blot, IHC, and immunoprecipitation applications .

How should I design controls when studying SH2D5 in different experimental contexts?

Proper control design is essential for research validity when working with SH2D5:

For Western blot analysis:

• Positive controls: Lysates from cells transiently transfected with SH2D5 expression vectors

• Negative controls: Lysates from cells with confirmed low/no SH2D5 expression

• Loading controls: β-actin, GAPDH for normalization

• Knockdown controls: Samples treated with validated SH2D5 siRNAs

For IHC experiments:

• Tissue controls: Include known positive tissues (brain regions with high SH2D5)

• Negative controls: Replace primary antibody with isotype-matched IgG

• Internal controls: Assess non-tumor tissue within the same section

• Quantification controls: Use standardized scoring systems (0-7 scale)

For functional studies:

• Vector controls: Empty vector transfections for overexpression studies

• siRNA controls: Non-targeting siRNA sequences for knockdown experiments

• Rescue experiments: Re-express siRNA-resistant SH2D5 to confirm specificity

• Pathway controls: Include AKT/STAT3 pathway activators/inhibitors to validate signaling mechanisms

For interaction studies:

• Domain controls: Test individual SH2D5 domains (PTB domain, SH2 domain)

• Binding site mutants: Create NxxF motif mutants to validate specific interactions

• Reciprocal co-IPs: Pull down with antibodies against both SH2D5 and putative partners

What considerations are important when selecting SH2D5 antibodies for different applications?

When selecting SH2D5 antibodies for specific applications, consider these key factors:

• Antibody type and target epitope:

  • Polyclonal antibodies: Offer higher sensitivity but potentially lower specificity

  • Monoclonal antibodies: Provide consistent specificity but may be less sensitive

  • Target epitope location: N-terminal (PTB domain) vs. C-terminal (SH2 domain)

  • Species reactivity: Human vs. mouse SH2D5 (based on your experimental model)

• Application-specific selection criteria:

  Application	Key Considerations	Recommended Validation
  Western blot	Denaturing conditions require linear epitope recognition	Test with positive control lysates, verify single band at expected MW
  IHC	Fixation effects on epitope accessibility	Validate in known positive tissues, optimize antigen retrieval
  IP	Native conformation recognition	Confirm pull-down efficiency, test in multiple cell lines
  Flow cytometry	Cell surface vs. intracellular protocols	Verify with permeabilization controls if intracellular

• Validation documentation:

  • Prioritize antibodies with published validation in your specific application

  • Review validation data showing specificity in knockout/knockdown models

  • Consider antibodies used in similar experimental contexts

  • Check for batch-to-batch consistency reports

• Technical specifications:

  • Recommended working dilutions for each application

  • Storage conditions and shelf-life

  • Clone information for monoclonals

  • Immunogen details to understand epitope location